BIO-Europe 2026
Cologne, Germany
November 9-11, 2026
Latest News
- Aplagon Appoints Carl Lindgren as Board Chair to Guide Later Stage Clinical and Corporate Development 29 June 2026
- Aplagon Announces EUR 5 Million Financing to Broaden Phase 2 Trials of its APAC Therapy in Thrombo-Inflammatory Diseases 16 June 2026
- Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases 1 June 2026
- Aplagon Announces First Patient Dosed in Phase 2a Clinical Trial of APAC in Patients with Peripheral Arterial Occlusive Disease / Chronic Limb Threatening Ischemia 12 March 2026
- Aplagon Announces EUR 7 Million Financing to Advance its APAC Therapeutic for Thrombo-Inflammatory Diseases into Phase 2A Clinical Trials 3 February 2025
- First Patient Dosed in the CHASE Clinical Trial for Aplagon’s APAC Therapeutic for Thrombo-Inflammatory Diseases 24 October 2024
- Aplagon Signed EIC-Accelerator Grant Agreement 16 November 2022
- Aplagon Joins The TRACER Excellence Program to Perform In-Human Imaging Study 8 September 2022
- First Patient Treated in First Clinical Study for Aplagon’s APAC 7 June 2022
- Aplagon Publishes New Data in Prestigious Journal of Cardiovascular Pharmacology 1 September 2021
- Aplagon Closes Oversubscribed EUR 2.2M Funding Round 28 May 2021
- Aplagon Partners with Cadila Pharmaceuticals to Develop and Commercialize APAC First-in-Class Antithrombotics for the Prevention of Blood Vessel Occlusions Related to Vascular Interventions 19 September 2017
Events
Aplagon will be represented at the following partnering or scientific meetings.
